Published in Transplantation on September 27, 2004
BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant (2009) 1.06
B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. Am J Transplant (2012) 1.03
Development of tolerogenic strategies in the clinic. Philos Trans R Soc Lond B Biol Sci (2005) 0.86
Human leukocyte antigen antibodies for monitoring transplant patients. Surg Today (2005) 0.86
Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques. Am J Transplant (2012) 0.85
B-cell tolerance in transplantation: is repertoire remodeling the answer? Expert Rev Clin Immunol (2009) 0.80
The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation (2016) 0.79
Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy. Transplantation (2007) 0.78
Alemtuzumab as compared to alternative contemporary induction regimens. Transpl Int (2012) 0.77
Cross-talk between T and B Cells in the Germinal Center following Transplantation. Transplantation (2016) 0.75
The Value of Protocol Biopsies to Identify Patients with De Novo Donor Specific Antibody at High Risk for Allograft Loss. Am J Transplant (2016) 0.75
Tolerogenicity of donor major histocompatibility complex-matched skin grafts in previously tolerant Massachusetts general hospital miniature swine. Transplantation (2012) 0.75
Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med (2013) 7.40
Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol (2011) 3.70
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol (2002) 3.05
Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant (2003) 2.83
FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet (2012) 2.74
Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation (2009) 2.28
Liver transplantation for the treatment of hepatocellular carcinoma. Oncology (Williston Park) (2011) 2.14
Biologics in organ transplantation. Transpl Int (2012) 2.06
Biliary complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long-term outcomes from a single center. Ann Surg (2011) 1.98
Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat (2007) 1.85
Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation (2003) 1.80
Immune regulation and graft survival in kidney transplant recipients are both enhanced by human leukocyte antigen matching. Am J Transplant (2004) 1.77
HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res (2006) 1.71
Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int (2006) 1.68
Donation after cardiac death: the University of Wisconsin experience with liver transplantation. Ann Surg (2005) 1.67
Developmental exposure to noninherited maternal antigens induces CD4+ T regulatory cells: relevance to mechanism of heart allograft tolerance. J Immunol (2007) 1.64
Microchimerism is strongly correlated with tolerance to noninherited maternal antigens in mice. Blood (2009) 1.63
Pretransplant immune regulation predicts allograft outcome: bidirectional regulation correlates with excellent renal transplant function in living-related donor-recipient pairs. Transplantation (2012) 1.63
All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation (2002) 1.58
Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Transpl Int (2013) 1.50
Tubular expression of heat-shock protein 27 inhibits fibrogenesis in obstructive nephropathy. Kidney Int (2012) 1.50
HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies. Mol Immunol (2009) 1.50
Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl (2010) 1.48
Mimetic human leukocyte antigen epitopes: shown by monoclonal antibodies and extra antibodies produced on transplantation. Transplantation (2008) 1.47
Selenium-binding protein-1 in smooth muscle cells is downregulated in a rhesus monkey model of chronic allograft nephropathy. Am J Transplant (2005) 1.45
Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Transpl Int (2008) 1.44
Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation (2008) 1.44
Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant (2004) 1.42
When Do DCD Donors Die?: Outcomes and Implications of DCD at a High-volume, Single-center OPO in the United States. Ann Surg (2016) 1.42
"Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation (2008) 1.41
Transition to invasion in breast cancer: a microfluidic in vitro model enables examination of spatial and temporal effects. Integr Biol (Camb) (2010) 1.41
Control of 3-dimensional collagen matrix polymerization for reproducible human mammary fibroblast cell culture in microfluidic devices. Biomaterials (2009) 1.37
Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol (2005) 1.36
Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J Biol Chem (2007) 1.35
Tolerance to noninherited maternal MHC antigens in mice. J Immunol (2003) 1.33
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation (2013) 1.33
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol (2003) 1.33
Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol (2009) 1.29
HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation (2006) 1.29
Donation after cardiac death: the university of wisconsin experience with renal transplantation. Am J Transplant (2004) 1.26
Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation (2009) 1.26
Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J Immunol (2007) 1.23
HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation (2009) 1.23
Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res (2005) 1.23
Risk factors and outcomes in post-liver transplantation bile duct stones and casts: A case-control study. Liver Transpl (2008) 1.23
Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am J Pathol (2006) 1.21
Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant (2004) 1.19
Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res (2004) 1.18
Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery (2004) 1.18
Donation after cardiac death: a 29-year experience. Surgery (2011) 1.18
The transcription factor REST is lost in aggressive breast cancer. PLoS Genet (2010) 1.17
Overcoming Chronic Rejection-Can it B? Transplantation (2009) 1.17
Metastable tolerance to rhesus monkey renal transplants is correlated with allograft TGF-beta 1+CD4+ T regulatory cell infiltrates. J Immunol (2004) 1.17
Nomenclature for Factors of the HLA System, 2004. Hum Immunol (2005) 1.14
Long-term outcomes in pediatric renal transplant recipients who survive into adulthood. Transplantation (2003) 1.14
Donation after cardiac death: the University of Wisconsin experience. Ann Transplant (2004) 1.14
Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Res Treat (2006) 1.14
3D microchannel co-culture: method and biological validation. Integr Biol (Camb) (2010) 1.13
Campath-1H use in pediatric renal transplantation. Am J Transplant (2005) 1.13
Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility. Am J Pathol (2010) 1.13
Natural resistance to liver cold ischemia-reperfusion injury associated with the hibernation phenotype. Am J Physiol Gastrointest Liver Physiol (2005) 1.13
Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res (2012) 1.12
T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation (2006) 1.12
The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation (2013) 1.11
Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol (2008) 1.10
Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl (2012) 1.10
The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int (2006) 1.08
Validation of large particle flow cytometry for the analysis and sorting of intact pancreatic islets. Transplantation (2005) 1.08
Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol (2002) 1.05
Frequency of MIC antibody in rejected renal transplant patients without HLA antibody. Hum Immunol (2006) 1.05
Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation (2010) 1.05
CXCR3-mediated T-cell chemotaxis involves ZAP-70 and is regulated by signalling through the T-cell receptor. Immunology (2007) 1.04
Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models. PLoS One (2013) 1.04
Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis. Cancer Res (2009) 1.04
Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. Am J Transplant (2004) 1.03
Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. Specific role for glypican-1 in glioma angiogenesis. J Biol Chem (2003) 1.02
Lack of association between EBV and breast carcinoma. Cancer Epidemiol Biomarkers Prev (2005) 1.02
Interleukin-23 is required for development of arthritis in mice vaccinated and challenged with Borrelia species. Clin Vaccine Immunol (2008) 1.02
Xenogeneic transplantation of porcine islets: an overview. Transplantation (2003) 1.00
Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Res (2008) 1.00
Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes (2012) 0.99
Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett (2002) 0.99
Underutilization of pancreas donors. Transplantation (2003) 0.98
Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J Rheumatol (2009) 0.98
AIDS-related Kaposi's sarcoma of the gastrointestinal tract. J Clin Oncol (2010) 0.97
Interleukin-17-dependent autoimmunity to collagen type V in atherosclerosis. Circ Res (2010) 0.97
Prevention of chronic allograft nephropathy with vitamin D. Transpl Int (2005) 0.96
Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry. Clin Transpl (2006) 0.96